Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.

Studied

A post-hoc pooled participant-level analysis combined four randomized placebo-controlled semaglutide trials to examine heart-failure events.

Who / model

The analysis included people with investigator-reported HFpEF drawn from trials enrolling obesity-related HFpEF, cardiovascular disease with overweight or obesity, or diabetes with chronic kidney disease.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Semaglutide reduced the combined risk of cardiovascular death or worsening heart failure and reduced worsening heart-failure events alone; cardiovascular death alone was not significantly reduced.

Limits

This was a post-hoc pooled analysis across trials with different entry populations and semaglutide doses.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary